SCHEMBL25073316

SCHEMBL25073316

O=C(O)Cc1ccc(NS(=O)(=O)c2cnc(-c3ccc(F)cc3)s2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ LMNA P02545 2/20 0.44
▸ PTPN11 Q06124 1/20 0.44
▸ POLB P06746 2/20 0.44
▸ PTGDR2 Q9Y5Y4 3/20 0.43
▸ PDE4B Q07343 2/20 0.42
▸ PDE4D Q08499 2/20 0.42
▸ MEN1 O00255 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ GLA P06280 1/20 0.39
▸ HSP90AA1 P07900 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ RORC P51449 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25072418 0.87 PTPN11 (0.44) GAAALDH1A1PTPN11POLBMEN1
SCHEMBL25073248 0.86 MEN1 (0.42) ALDH1A1LMNAPTPN11PTGDR2MEN1
SCHEMBL25072408 0.86 PTPN11 (0.51) GAAALDH1A1PTPN11POLBMEN1
SCHEMBL25073280 0.84 PTPN11 (0.45) GAAALDH1A1LMNAPTPN11POLB
SCHEMBL25073315 0.84 KMT2A (0.49) GAAALDH1A1LMNAPTPN11POLB
SCHEMBL25073308 0.83 P4HTM (0.49) GAAALDH1A1PTPN11POLBMEN1
SCHEMBL25073028 0.82 PTPN11 (0.44) GAAALDH1A1PTPN11POLBMEN1
SCHEMBL25072887 0.82 ALDH1A1 (0.46) GAAALDH1A1PTPN11POLBMEN1
SCHEMBL25073360 0.81 FABP4 (0.45) GAAALDH1A1LMNAPTPN11POLB
SCHEMBL25073205 0.79 HDAC1 (0.45) ALDH1A1PTPN11MAPTKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
WO-2023023310-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2023-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF HSD17B1, HSD17B13, HSD17B3 GAA 389/4885ALDH1A1 125/4885LMNA 2111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback